Furthermore, in a meta-analysis of phase II/III trials comparing ICIs (nivolumab, pembrolizumab, and, atezolizumab) with docetaxel in the second-line treatment of NSCLC, the OS of ICIs vs. digital therapeutics (DTX) in patients with EGFR mutations was hazard ratio (HR) 1.11 [95% confidence intervals (CI): 0.80–1.53, P = 0.54], indicating that although efficacy has been demonstrated in the overall population, treatment with ICIs is not superior in patients with EGFR mutation-positive [37]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.